# Efficacy and Safety of Meteospasmyl® in Irritable Bowel Syndrome

> **NCT00542295** · PHASE4 · COMPLETED · sponsor: **Laboratoires Mayoly Spindler** · enrollment: 400 (estimated)

## Conditions studied

- Irritable Bowel Syndrome

## Interventions

- **DRUG:** alverine citrate and simeticone
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00542295
- **Lead sponsor:** Laboratoires Mayoly Spindler
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2008-07
- **Final completion:** 2008-09
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2008-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00542295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00542295, "Efficacy and Safety of Meteospasmyl® in Irritable Bowel Syndrome". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00542295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*